Recent advances in site specific conjugations of antibody drug conjugates (ADCs)

Current Cancer Drug Targets

Volumn 16, Issue 6, 2016, Pages 469-479

  Gao, Wenlong ^a   Zhang, Jingxin ^b   Xiang, Jun ^a   Zhang, Lei ^a   Wu, Chengbin ^a   Dhal, Pradeep K ^b   Chen, Bo ^a,c  

^a Shanghai Allist Pharmaceut Co Inc   (China)

^b SANOFI   (United States)

^c Vifor (International) Inc   (Switzerland)

Author keywords

ADCs; Antibody drug conjugates; Conjugation site; DAR; Homogeneous ADCs; Site specific conjugation

Indexed keywords

ANTIBODY CONJUGATE; BRENTUXIMAB VEDOTIN; CD30 ANTIGEN; CYTOTOXIC AGENT; IMMUNOGLOBULIN G1 ANTIBODY; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE; SORTASE; TRASTUZUMAB; TRASTUZUMAB EMTANSINE; VEDOTIN; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ANTIGEN SPECIFICITY; ANTINEOPLASTIC ACTIVITY; DRUG CONJUGATION; DRUG DESIGN; DRUG EFFICACY; DRUG RESEARCH; DRUG SAFETY; DRUG STABILITY; DRUG TARGETING; IMMUNOGENICITY; PHARMACOKINETIC PARAMETERS; REVIEW; STOICHIOMETRY; STRUCTURE ACTIVITY RELATION; TOXICITY; ANIMAL; ANTIBODY SPECIFICITY; HUMAN; IMMUNOLOGY; NEOPLASMS;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY SPECIFICITY; ANTINEOPLASTIC AGENTS; HUMANS; IMMUNOCONJUGATES; NEOPLASMS;

EID: 84978272068     PISSN: 15680096     EISSN: 18735576     Source Type: Journal    
DOI: 10.2174/1568009616666160512144715     Document Type: Review

References (74)

1. Schwartz, R. S. Paul Ehrlich's magic bullets. N. Engl. J. Med., 2004, 350(11), 1079-1080.
2. Perez, H. L.; Cardarelli, P. M.; Deshpande, S.; Gangwar, S.; Schroeder, G. M.; Vite, G. D.; Borzilleri, R. M. Antibody-drug conjugates: current status and future directions. Drug Discov. Today, 2014, 19(7), 869-881.
3. Goldmacher, V. S.; Kovtun, Y. V. Antibody-drug conjugates: using monoclonal antibodies for delivery of cytotoxic payloads to cancer cells. Ther. Deliv., 2011, 2(3), 397-416.
4. Sievers, E. L.; Senter, P. D. Antibody-drug conjugates in cancer therapy. Annu. Rev. Med., 2013, 64, 15-29.
5. Jackson, D.; Stover, D. Using the lessons learned from the clinic to improve the preclinical development of antibody drug conjugates. Pharm. Res., 2015, 32(11), 3458-3469.
6. Mack, F.; Ritchie, M.; Sapra, P. The next generation of antibody drug conjugates. Semin. Oncol., 2014, 41(5), 637-652.
7. McCombs, J. R.; Owen, S. C. Antibody Drug Conjugates: Design and Selection of Linker, Payload and Conjugation Chemistry. AAPS J., 2015, 17(2), 339-351.
8. Sievers, E. L.; Linenberger, M. Mylotarg: antibody-targeted chemotherapy comes of age. Curr. Opin. Oncol., 2001, 13(6), 522-527.
9. Ravandi, F. Gemtuzumab ozogamicin: one size does not fit all-the case for personalized therapy. J. Clin. Oncol., 2011, 29(4), 349-351.
10. Doronina, S. O.; Toki, B. E.; Torgov, M. Y.; Mendelsohn, B. A.; Cerveny, C. G.; Chace, D. F.; DeBlanc, R. L.; Gearing, R. P.; Bovee, T. D.; Siegall, C. B.; Francisco, J. A.; Wahl, A. F.; Meyer, D. L.; Senter, P. D. Development of potent monoclonal antibody auristatin conjugates for cancer therapy. Nat. Biotechnol., 2003, 21(7), 778-784.
11. Senter, P. D.; Sievers, E. L. The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma. Nat. Biotechnol., 2012, 30(7), 631-637.
12. Lewis Phillips, G. D.; Li, G.; Dugger, D. L.; Crocker, L. M.; Parsons, K. L.; Mai, E.; Blattler, W. A.; Lambert, J. M.; Chari, R. V.; Lutz, R. J.; Wong, W. L.; Jacobson, F. S.; Koeppen, H.; Schwall, R. H.; Kenkare-Mitra, S. R.; Spencer, S. D.; Sliwkowski, M. X. Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibodycytotoxic drug conjugate. Cancer Res., 2008, 68(22), 9280-9290.
13. Amiri-Kordestani, L.; Blumenthal, G. M.; Xu, Q. C.; Zhang, L.; Tang, S. W.; Ha, L.; Weinberg, W. C.; Chi, B.; Candau-Chacon, R.; Hughes, P.; Russell, A. M.; Miksinski, S. P.; Chen, X. H.; McGuinn, W. D.; Palmby, T.; Schrieber, S. J.; Liu, Q.; Wang, J.; Song, P.; Mehrotra, N.; Skarupa, L.; Clouse, K.; Al-Hakim, A.; Sridhara, R.; Ibrahim, A.; Justice, R.; Pazdur, R.; Cortazar, P. FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin. Cancer Res., 2014, 20(17), 4436-4441.
14. Mullard, A. Maturing antibody-drug conjugate pipeline hits 30. Nat. Rev. Drug Discov., 2013, 12(5), 329-332.
15. Sun, M. M.; Beam, K. S.; Cerveny, C. G.; Hamblett, K. J.; Blackmore, R. S.; Torgov, M. Y.; Handley, F. G.; Ihle, N. C.; Senter, P. D.; Alley, S. C. Reduction-alkylation strategies for the modification of specific monoclonal antibody disulfides. Bioconjug. Chem., 2005, 16(5), 1282-1290.
16. Wang, L.; Amphlett, G.; Blattler, W. A.; Lambert, J. M.; Zhang, W. Structural characterization of the maytansinoid-monoclonal antibody immunoconjugate, huN901-DM1, by mass spectrometry. Protein Sci., 2005, 14(9), 2436-2446.
17. Hamblett, K. J.; Senter, P. D.; Chace, D. F.; Sun, M. M.; Lenox, J.; Cerveny, C. G.; Kissler, K. M.; Bernhardt, S. X.; Kopcha, A. K.; Zabinski, R. F.; Meyer, D. L.; Francisco, J. A. Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate. Clin. Cancer Res., 2004, 10(20), 7063-7070.
18. Behrens, C. R.; Liu, B. Methods for site-specific drug conjugation to antibodies. MAbs, 2014, 6(1), 46-53.
19. Panowksi, S.; Bhakta, S.; Raab, H.; Polakis, P.; Junutula, J. R. Sitespecific antibody drug conjugates for cancer therapy. MAbs, 2014, 6(1), 34-45.
20. Junutula, J. R.; Raab, H.; Clark, S.; Bhakta, S.; Leipold, D. D.; Weir, S.; Chen, Y.; Simpson, M.; Tsai, S. P.; Dennis, M. S.; Lu, Y.; Meng, Y. G.; Ng, C.; Yang, J.; Lee, C. C.; Duenas, E.; Gorrell, J.; Katta, V.; Kim, A.; McDorman, K.; Flagella, K.; Venook, R.; Ross, S.; Spencer, S. D.; Lee Wong, W.; Lowman, H. B.; Vandlen, R.; Sliwkowski, M. X.; Scheller, R. H.; Polakis, P.; Mallet, W. Sitespecific conjugation of a cytotoxic drug to an antibody improves the therapeutic index. Nat. Biotechnol., 2008, 26(8), 925-932.
21. Junutula, J. R.; Flagella, K. M.; Graham, R. A.; Parsons, K. L.; Ha, E.; Raab, H.; Bhakta, S.; Nguyen, T.; Dugger, D. L.; Li, G.; Mai, E.; Lewis Phillips, G. D.; Hiraragi, H.; Fuji, R. N.; Tibbitts, J.; Vandlen, R.; Spencer, S. D.; Scheller, R. H.; Polakis, P.; Sliwkowski, M. X. Engineered thio-trastuzumab-DM1 conjugate with an improved therapeutic index to target human epidermal growth factor receptor 2-positive breast cancer. Clin. Cancer Res., 2010, 16(19), 4769-4778.
22. Bhakta, S.; Raab, H.; Junutula, J. R. Engineering THIOMABs for site-specific conjugation of thiol-reactive linkers. Methods Mol. Biol., 2013, 1045, 189-203.
23. Shen, B. Q.; Xu, K.; Liu, L.; Raab, H.; Bhakta, S.; Kenrick, M.; Parsons-Reponte, K. L.; Tien, J.; Yu, S. F.; Mai, E.; Li, D.; Tibbitts, J.; Baudys, J.; Saad, O. M.; Scales, S. J.; McDonald, P. J.; Hass, P. E.; Eigenbrot, C.; Nguyen, T.; Solis, W. A.; Fuji, R. N.; Flagella, K. M.; Patel, D.; Spencer, S. D.; Khawli, L. A.; Ebens, A.; Wong, W. L.; Vandlen, R.; Kaur, S.; Sliwkowski, M. X.; Scheller, R. H.; Polakis, P.; Junutula, J. R. Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates. Nat. Biotechnol., 2012, 30(2), 184-189.
24. Pillow, T. H.; Tien, J.; Parsons-Reponte, K. L.; Bhakta, S.; Li, H.; Staben, L. R.; Li, G.; Chuh, J.; Fourie-O'Donohue, A.; Darwish, M.; Yip, V.; Liu, L.; Leipold, D. D.; Su, D.; Wu, E.; Spencer, S. D.; Shen, B. Q.; Xu, K.; Kozak, K. R.; Raab, H.; Vandlen, R.; Lewis Phillips, G. D.; Scheller, R. H.; Polakis, P.; Sliwkowski, M. X.; Flygare, J. A.; Junutula, J. R. Site-specific trastuzumab maytansinoid antibody-drug conjugates with improved therapeutic activity through linker and antibody engineering. J. Med. Chem., 2014, 57(19), 7890-7899.
25. Axup, J. Y.; Bajjuri, K. M.; Ritland, M.; Hutchins, B. M.; Kim, C. H.; Kazane, S. A.; Halder, R.; Forsyth, J. S.; Santidrian, A. F.; Stafin, K.; Lu, Y.; Tran, H.; Seller, A. J.; Biroc, S. L.; Szydlik, A.; Pinkstaff, J. K.; Tian, F.; Sinha, S. C.; Felding-Habermann, B.; Smider, V. V.; Schultz, P. G. Synthesis of site-specific antibody-drug conjugates using unnatural amino acids. Proc. Natl. Acad. Sci. USA, 2012, 109(40), 16101-16106.
26. Tian, F.; Lu, Y.; Manibusan, A.; Sellers, A.; Tran, H.; Sun, Y.; Phuong, T.; Barnett, R.; Hehli, B.; Song, F.; DeGuzman, M. J.; Ensari, S.; Pinkstaff, J. K.; Sullivan, L. M.; Biroc, S. L.; Cho, H.; Schultz, P. G.; DiJoseph, J.; Dougher, M.; Ma, D.; Dushin, R.; Leal, M.; Tchistiakova, L.; Feyfant, E.; Gerber, H. P.; Sapra, P. A general approach to site-specific antibody drug conjugates. Proc. Natl. Acad. Sci. USA, 2014, 111(5), 1766-1771.
27. Zimmerman, E. S.; Heibeck, T. H.; Gill, A.; Li, X.; Murray, C. J.; Madlansacay, M. R.; Tran, C.; Uter, N. T.; Yin, G.; Rivers, P. J.; Yam, A. Y.; Wang, W. D.; Steiner, A. R.; Bajad, S. U.; Penta, K.; Yang, W.; Hallam, T. J.; Thanos, C. D.; Sato, A. K. Production of site-specific antibody-drug conjugates using optimized non-natural amino acids in a cell-free expression system. Bioconjug. Chem., 2014, 25(2), 351-361.
28. Hofer, T.; Skeffington, L. R.; Chapman, C. M.; Rader, C. Molecularly defined antibody conjugation through a selenocysteine interface. Biochemistry., 2009, 48(50), 12047-12057.
29. Li, X.; Yang, J.; Rader, C. Antibody conjugation via one and two C-terminal selenocysteines. Methods, 2014, 65(1), 133-138.
30. Farias, S. E.; Strop, P.; Delaria, K.; Galindo Casas, M.; Dorywalska, M.; Shelton, D. L.; Pons, J.; Rajpal, A. Mass spectrometric characterization of transglutaminase based site-specific antibodydrug conjugates. Bioconjug. Chem., 2014, 25(2), 240-250.
31. Lhospice, F.; Bregeon, D.; Belmant, C.; Dennler, P.; Chiotellis, A.; Fischer, E.; Gauthier, L.; Boedec, A.; Rispaud, H.; Savard-Chambard, S.; Represa, A.; Schneider, N.; Paturel, C.; Sapet, M.; Delcambre, C.; Ingoure, S.; Viaud, N.; Bonnafous, C.; Schibli, R.; Romagne, F. Site-specific conjugation of monomethyl auristatin E to anti-CD30 antibodies improves their pharmacokinetics and therapeutic index in rodent models. Mol. Pharm., 2015, 12(6), 1863-1871.
32. Jeger, S.; Zimmermann, K.; Blanc, A.; Grunberg, J.; Honer, M.; Hunziker, P.; Struthers, H.; Schibli, R. Site-specific and stoichiometric modification of antibodies by bacterial transglutaminase. Angew. Chem. Int. Ed. Engl., 2010, 49(51), 9995-9997.
33. Zhou, Q.; Stefano, J. E.; Manning, C.; Kyazike, J.; Chen, B.; Gianolio, D. A.; Park, A.; Busch, M.; Bird, J.; Zheng, X.; Simonds-Mannes, H.; Kim, J.; Gregory, R. C.; Miller, R. J.; Brondyk, W. H.; Dhal, P. K.; Pan, C. Q. Site-specific antibody-drug conjugation through glycoengineering. Bioconjug. Chem., 2014, 25(3), 510-520.
34. Zhu, Z.; Ramakrishnan, B.; Li, J.; Wang, Y.; Feng, Y.; Prabakaran, P.; Colantonio, S.; Dyba, M. A.; Qasba, P. K.; Dimitrov, D. S. Sitespecific antibody-drug conjugation through an engineered glycotransferase and a chemically reactive sugar. MAbs, 2014, 6(5), 1190-1200.
35. Albers, A. E.; Garofalo, A. W.; Drake, P. M.; Kudirka, R.; de Hart, G. W.; Barfield, R. M.; Baker, J.; Banas, S.; Rabuka, D. Exploring the effects of linker composition on site-specifically modified antibody-drug conjugates. Eur. J. Med. Chem., 2014, 88, 3-9.
36. Drake, P. M.; Albers, A. E.; Baker, J.; Banas, S.; Barfield, R. M.; Bhat, A. S.; de Hart, G. W.; Garofalo, A. W.; Holder, P.; Jones, L. C.; Kudirka, R.; McFarland, J.; Zmolek, W.; Rabuka, D. Aldehyde tag coupled with HIPS chemistry enables the production of ADCs conjugated site-specifically to different antibody regions with distinct in vivo efficacy and PK outcomes. Bioconjug. Chem., 2014, 25(7), 1331-1341.
37. Kline, T.; Steiner, A. R.; Penta, K.; Sato, A. K.; Hallam, T. J.; Yin, G. Methods to make homogenous antibody drug conjugates. Pharm. Res., 2014, 32(11), 3480-3493.
38. Badescu, G.; Bryant, P.; Bird, M.; Henseleit, K.; Swierkosz, J.; Parekh, V.; Tommasi, R.; Pawlisz, E.; Jurlewicz, K.; Farys, M.; Camper, N.; Sheng, X.; Fisher, M.; Grygorash, R.; Kyle, A.; Abhilash, A.; Frigerio, M.; Edwards, J.; Godwin, A. Bridging disulfides for stable and defined antibody drug conjugates. Bioconjug. Chem., 2014, 25(6), 1124-1136.
39. Schumacher, F. F.; Nunes, J. P.; Maruani, A.; Chudasama, V.; Smith, M. E.; Chester, K. A.; Baker, J. R.; Caddick, S. Next generation maleimides enable the controlled assembly of antibodydrug conjugates via native disulfide bond bridging. Org. Biomol. Chem., 2014, 12(37), 7261-7269.
40. Scheck, R. A.; Francis, M. B. Regioselective labeling of antibodies through N-terminal transamination. ACS Chem. Biol., 2007, 2(4), 247-251.
41. Witus, L. S.; Netirojjanakul, C.; Palla, K. S.; Muehl, E. M.; Weng, C. H.; Iavarone, A. T.; Francis, M. B. Site-specific protein transamination using N-methylpyridinium-4-carboxaldehyde. J. Am. Chem. Soc., 2013, 135(45), 17223-17229.
42. Liu, W.; Brock, A.; Chen, S.; Chen, S.; Schultz, P. G. Genetic incorporation of unnatural amino acids into proteins in mammalian cells. Nat. Methods, 2007, 4(3), 239-244.
43. Hutchins, B. M.; Kazane, S. A.; Staflin, K.; Forsyth, J. S.; Felding-Habermann, B.; Schultz, P. G.; Smider, V. V. Site-specific coupling and sterically controlled formation of multimeric antibody fab fragments with unnatural amino acids. J. Mol. Biol., 2011, 406(4), 595-603.
44. Hallam, T. J.; Smider, V. V. Unnatural amino acids in novel antibody conjugates. Future Med. Chem., 2014, 6(11), 1309-1324.
45. Yokoyama, K.; Nio, N.; Kikuchi, Y. Properties and applications of microbial transglutaminase. Appl. Microbiol. Biotechnol., 2004, 64(4), 447-454.
46. Dennler, P.; Schibli, R.; Fischer, E. Enzymatic antibody modification by bacterial transglutaminase. Methods Mol. Biol., 2013, 1045, 205-215.
47. Dennler, P.; Chiotellis, A.; Fischer, E.; Bregeon, D.; Belmant, C.; Gauthier, L.; Lhospice, F.; Romagne, F.; Schibli, R. Transglutaminase-based chemo-enzymatic conjugation approach yields homogeneous antibody-drug conjugates. Bioconjug. Chem., 2014, 25(3), 569-578.
48. Ramakrishnan, B.; Qasba, P. K. Structure-based design of beta 1, 4-galactosyltransferase I (beta 4Gal-T1) with equally efficient Nacetylgalactosaminyltransferase activity: point mutation broadens beta 4Gal-T1 donor specificity. J. Biol. Chem., 2002, 277(23), 20833-20839.
49. Qasba, P. K.; Boeggeman, E.; Ramakrishnan, B. Site-specific linking of biomolecules via glycan residues using glycosyltransferases. Biotechnol. Prog., 2008, 24(3), 520-526.
50. Ramakrishnan, B.; Boeggeman, E.; Qasba, P. K. Applications of glycosyltransferases in the site-specific conjugation of biomolecules and the development of a targeted drug delivery system and contrast agents for MRI. Expert Opin. Drug Deliv., 2008, 5(2), 149-153.
51. Boeggeman, E.; Ramakrishnan, B.; Pasek, M.; Manzoni, M.; Puri, A.; Loomis, K. H.; Waybright, T. J.; Qasba, P. K. Site specific conjugation of fluoroprobes to the remodeled Fc N-glycans of monoclonal antibodies using mutant glycosyltransferases: application for cell surface antigen detection. Bioconjug. Chem., 2009, 20(6), 1228-1236.
52. Dulcey, A. E.; Qasba, P. K.; Lamb, J.; Griffiths, G. L. Improved synthesis of UDP-2-(2-ketopropyl)galactose and a first synthesis of UDP-2-(2-ketopropyl)glucose for the site-specific linking of biomolecules via modified glycan residues using glycosyltransferases. Tetrahedron, 2011, 67(11), 2013-2017.
53. Zhou, Q.; Stefano, J. E.; Harrahy, J.; Finn, P.; Avila, L.; Kyazike, J.; Wei, R.; Van Patten, S. M.; Gotschall, R.; Zheng, X.; Zhu, Y.; Edmunds, T.; Pan, C. Q. Strategies for Neoglycan conjugation to human acid alpha-glucosidase. Bioconjug. Chem., 2011, 22(4), 741-751.
54. Carrico, I. S.; Carlson, B. L.; Bertozzi, C. R. Introducing genetically encoded aldehydes into proteins. Nat. Chem. Biol., 2007, 3(6), 321-322.
55. Wu, P.; Shui, W.; Carlson, B. L.; Hu, N.; Rabuka, D.; Lee, J.; Bertozzi, C. R. Site-specific chemical modification of recombinant proteins produced in mammalian cells by using the genetically encoded aldehyde tag. Proc. Natl. Acad. Sci. USA, 2009, 106(9), 3000-3005.
56. Rabuka, D.; Rush, J. S.; deHart, G. W.; Wu, P.; Bertozzi, C. R. Sitespecific chemical protein conjugation using genetically encoded aldehyde tags. Nat. Protoc., 2012, 7(6), 1052-1067.
57. Kudirka, R.; Barfield, R. M.; McFarland, J.; Albers, A. E.; de Hart, G. W.; Drake, P. M.; Holder, P. G.; Banas, S.; Jones, L. C.; Garofalo, A. W.; Rabuka, D. Generating site-specifically modified proteins via a versatile and stable nucleophilic carbon ligation. Chem. Biol., 2015, 22(2), 293-298.
58. Popp, M. W.; Antos, J. M.; Ploegh, H. L. Site-specific protein labeling via sortase-mediated transpeptidation. Curr. Protoc. Protein Sci., 2009, Chapter 15, Unit 1513.
59. Tsukiji, S.; Nagamune, T. Sortase-mediated ligation: a gift from Gram-positive bacteria to protein engineering. Chembiochem, 2009, 10(5), 787-798.
60. Madej, M. P.; Coia, G.; Williams, C. C.; Caine, J. M.; Pearce, L. A.; Attwood, R.; Bartone, N. A.; Dolezal, O.; Nisbet, R. M.; Nuttall, S. D.; Adams, T. E. Engineering of an anti-epidermal growth factor receptor antibody to single chain format and labeling by Sortase Amediated protein ligation. Biotechnol. Bioeng., 2012, 109(6), 1461-1470.
61. Ta, H. T.; Peter, K.; Hagemeyer, C. E. Enzymatic antibody tagging: toward a universal biocompatible targeting tool. Trends Cardiovasc. Med., 2012, 22(4), 105-111.
62. Guimaraes, C. P.; Witte, M. D.; Theile, C. S.; Bozkurt, G.; Kundrat, L.; Blom, A. E.; Ploegh, H. L. Site-specific C-terminal and internal loop labeling of proteins using sortase-mediated reactions. Nat. Protoc., 2013, 8(9), 1787-1799.
63. Theile, C. S.; Witte, M. D.; Blom, A. E.; Kundrat, L.; Ploegh, H. L.; Guimaraes, C. P. Site-specific N-terminal labeling of proteins using sortase-mediated reactions. Nat. Protoc., 2013, 8(9), 1800-1807.
64. Brocchini, S.; Balan, S.; Godwin, A.; Choi, J. W.; Zloh, M.; Shaunak, S. PEGylation of native disulfide bonds in proteins. Nat. Protoc., 2006, 1(5), 2241-2252.
65. Shaunak, S.; Godwin, A.; Choi, J. W.; Balan, S.; Pedone, E.; Vijayarangam, D.; Heidelberger, S.; Teo, I.; Zloh, M.; Brocchini, S. Site-specific PEGylation of native disulfide bonds in therapeutic proteins. Nat. Chem. Biol., 2006, 2(6), 312-313.
66. Balan, S.; Choi, J. W.; Godwin, A.; Teo, I.; Laborde, C. M.; Heidelberger, S.; Zloh, M.; Shaunak, S.; Brocchini, S. Site-specific PEGylation of protein disulfide bonds using a three-carbon bridge. Bioconjug. Chem., 2007, 18(1), 61-76.
67. Brocchini, S.; Godwin, A.; Balan, S.; Choi, J. W.; Zloh, M.; Shaunak, S. Disulfide bridge based PEGylation of proteins. Adv. Drug Deliv. Rev., 2008, 60(1), 3-12.
68. Smith, M. E.; Schumacher, F. F.; Ryan, C. P.; Tedaldi, L. M.; Papaioannou, D.; Waksman, G.; Caddick, S.; Baker, J. R. Protein modification, bioconjugation, and disulfide bridging using bromomaleimides. J. Am. Chem. Soc., 2010, 132 (6), 1960-1965.
69. Schumacher, F. F.; Nobles, M.; Ryan, C. P.; Smith, M. E.; Tinker, A.; Caddick, S.; Baker, J. R. In situ maleimide bridging of disulfides and a new approach to protein PEGylation. Bioconjug. Chem., 2011, 22(2), 132-136.
70. Schumacher, F. F.; Sanchania, V. A.; Tolner, B.; Wright, Z. V.; Ryan, C. P.; Smith, M. E.; Ward, J. M.; Caddick, S.; Kay, C. W.; Aeppli, G.; Chester, K. A.; Baker, J. R. Homogeneous antibody fragment conjugation by disulfide bridging introduces 'spinostics'. Sci. Rep., 2013, 3, 1525.
71. Kinstler, O.; Molineux, G.; Treuheit, M.; Ladd, D.; Gegg, C. Mono-N-terminal poly(ethylene glycol)-protein conjugates. Adv. Drug Deliv. Rev., 2002, 54(4), 477-485.
72. Gilmore, J. M.; Scheck, R. A.; Esser-Kahn, A. P.; Joshi, N. S.; Francis, M. B. N-terminal protein modification through a biomimetic transamination reaction. Angew. Chem. Int. Ed. Engl., 2006, 45(32), 5307-5311.
73. Scheck, R. A.; Dedeo, M. T.; Iavarone, A. T.; Francis, M. B. Optimization of a biomimetic transamination reaction. J. Am. Chem. Soc., 2008, 130(35), 11762-11770.
74. Strop, P.; Liu, S. H.; Dorywalska, M.; Delaria, K.; Dushin, R. G.; Tran, T. T.; Ho, W. H.; Farias, S.; Casas, M. G.; Abdiche, Y.; Zhou, D.; Chandrasekaran, R.; Samain, C.; Loo, C.; Rossi, A.; Rickert, M.; Krimm, S.; Wong, T.; Chin, S. M.; Yu, J.; Dilley, J.; Chaparro-Riggers, J.; Filzen, G. F.; O'Donnell, C. J.; Wang, F.; Myers, J. S.; Pons, J.; Shelton, D. L.; Rajpal, A. Location matters: site of conjugation modulates stability and pharmacokinetics of antibody drug conjugates. Chem. Biol., 2013, 20(2), 161-167.